Priapism, in which penile erection persists in the absence of sexual excitation, is an enigmatic yet devastating erectile disorder. Current endeavors to manage the disorder suffer from a poor fundamental knowledge of the etiology and pathogenesis of priapism. These endeavors have remained essentially reactive, which commonly fail to avert its pathological consequences of erectile tissue damage and erectile disability, not to mention its psychological toll. The role of preventative management seems paramount with respect to priapism. As a prerequisite to formulating prevention strategies, gaining understanding of its pathogenic features and likely pathophysiologic mechanisms is viewed to be quite important. This review combined an analysis of clinicopathologic reports as well as a summary of clinical and basic science investigations on the subject to date. These assessments support the basic classification of priapism into low-flow (ischemic) and high-flow (nonischemic) hemodynamic categories, resulting from venous outflow occlusion and unregulated arterial overflow of the penis, respectively. In addition, consistent with the hypothesis that dysregulative physiology of penile erection accounts for some presentations of priapism, several plausible molecular mechanisms influencing the functional state of the erectile tissue are discussed. Current progress in the field suggests prevention possibilities using androgenic suppressive therapy, adrenergic agonist therapies, and effectors of the nitric oxide-dependent erection regulatory pathway in the penis. New ideas for prevention may emerge from targeting molecular mechanisms involved in regulating erectile tissue function.
Introduction
Priapism, defined as prolonged penile erection in the absence of sexual stimulation, probably represents the greatest challenge in therapeutic management among erectile disorders. The disorder has an obscure etiology and often unpredictably affects select individuals without a clear pathogenic basis. Furthermore, it may cause significant physical and psychological debilitation, commonly rendering complete impotence in a young man who before its occurrence was sexually intact. Finally, treatments offered for the disorder often are administered too late to redress the problem fully or restore normal erectile function.
Conventional treatments in the field are mostly reactive, administered usually after the priapic episode has already happened. The knowledge that interventions offered subsequent to the onset of priapism are frequently inadequate emphasizes the role of prevention of the problem. However, while the optimal therapy for this disorder may be its prevention, the key element in this management practice is having a sound understanding about the pathogenic basis of the disorder. At this time, scientific ignorance persists in this regard. Such fundamental questions require resolution: What causes priapism? Who is most susceptible? Are there predisposing factors or conditions pertaining to its onset or recurrence? Is there scientific evidence for a pathophysiologic mechanism that can be targeted for preventive treatment?
To advance prevention objectives, further understanding about the pathophysiology of priapism is required. Insights, both now and in the future, will draw from clinical study as well as from basic science investigation in this field. Clinical study relates to epidemiologic approaches as well as to observations from procedures used to treat the disorder. Basic science investigation relates to unraveling the molecular determinants of the disorder, akin to the type of progress made recently in the field of erectile dysfunction. In this essay, we discuss the pathophysiology of priapism, with emphasis on these subject areas. The essay concludes with the postulate that priapism results from derangements in the complex, integrative control system involved in normal penile erection, from which new preventive strategies can be considered.
Abnormal penile blood flow
Frank Hinman Sr 1 can be credited with providing an early, comprehensive study of the pathophysiology of priapism. He understood the effects of and gave primary relevance to 'mechanical' disturbances involving the penile circulation, which he associated with 'thrombosis of the veins of the corpora'. He identified the relationship to priapism of such clinical conditions as pelvic abscess formation, penile tumorous growths, perineal or genital injury, and hematologic dyscrasias. His description provided the foundation for the concept of low-flow, ischemic priapism, in which a veno-occlusive pathology is believed to be a major cause of priapism.
Distinctive veno-occlusive pathologies include (see Table 1 ): sickle cell disease, which is associated with sickled erythrocytes producing a sludge effect; 2,3 parenteral hyperalimentation particularly combined with fat emulsion, which is associated with increased intravascular viscosity, stimulated blood coagulability, or the development of fat embolism; 4, 5 hemodialysis, which is associated with increased intravascular viscosity as a consequence of hemoconcentration and hypovolemia following treatment; 6 intracavernosal heparin administration, which is associated with increased blood coagulability paradoxically on the basis of its stimulating platelet aggregation; 7 local primary or metastatic neoplastic processes, which are associated with direct tumor infiltration and obstruction; [8] [9] [10] [11] and hematologic dyscrasias, which are also associated with tumor infiltration and obstruction from hematogenous spread. 8, 9 An additional concept for priapism resulting from disturbed blood flow is high-flow, nonischemic priapism, in which arterial overflow is considered to be pathogenic. 12, 13 Trauma seems to be the primary basis for this entity, either commonly from blunt trauma to the perineum or genitalia [14] [15] [16] or from vascular laceration such as that resulting from needle passage with intracavernosal pharmacotherapy 17 (see Table 2 ). Following trauma, the penile vasculature is structurally damaged, which permits uncontrolled blood entry and filling within the corpora cavernosa. Commonly, a fistula forms between arterial inflow vessels and the venous and sinusoidal outflow circulation of the penis. Penile arterial revascularization surgery for arteriogenic impotence provides another setting for the complication of high-flow priapism.
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Abnormal erection neuroregulation
A 'neural' variant of priapism was initially supported by Hinman Sr, who recognized that a substantial number of patients presenting with priapism exhibit neurologic disease. 1 He suggested that this form of priapism affected 'erectile centers' of the nervous system and included infections such as syphilis, brain tumors, epilepsy, intoxication, and brain and spinal cord injury as causative factors. 1 Several mechanisms have been proposed to explain how these neurologic diseases cause priapism, mostly in line with concepts related to the neuroregulatory basis for penile erections. One explanation pertains to abnormal activation of neural reflexogenic mechanisms involved in erection following genital stimulation. [20] [21] [22] [23] [24] Another explanation relates to disturbances in central neurotransmission that mediates penile erection. 25 Knowledge of the traditional autonomic sympathetic nervous system that mediates detumescence and penile flaccidity has supported the general belief that pathogenic failure of this system could readily predispose to the development of priapism. 26, 27 Priapism variants Priapism variants are worth examining briefly to acknowledge that they do not readily fit the contexts [28] [29] [30] has long been recognized as priapism occurring without a discernible clinical association. The variant has been associated with sporadic previous priapism episodes and particularly with erections that are sustained for prolonged durations of sexual activity. 26, [28] [29] [30] [31] Nocturnal erections have also been associated. 1, 26 'Stuttering' priapism, familiarly observed as frequently recurring priapism episodes in men with sickle cell disease, 32 has been associated with sleep and sexual arousal. [32] [33] [34] It is interesting that these episodes bear no relationship to other vaso-occlusive crises characteristic of sickle cell disease 35, 36 and may not always predispose to complete erectile dysfunction. 32, 33, 35 Refractory priapism, in reference to the recurrent erectile state that follows aspiration or incision of the corpora cavernosa for ischemic priapism, 2,31,37,38 has long been recognized but poorly understood. Some have contended that the blood flow pattern resembles high-flow priapism based on radiographic study, in the absence of an arterialcavernosal fistula. [37] [38] [39] [40] High-flow priapism has been clinically assessed in priapism related to medical diseases including Fabry's disease 41 and sickle cell disease. 37 Drug-induced priapism, which as suggested implies a medication-related phenomenon, represents another variant that has resulted from use of alpha-adrenergic antihypertensives, psychotropic agents, antidepressant medications, cocaine, and pharmacotherapeutic agents for erectile dysfunction. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] The mechanism of action is contended to relate to peripheral and central signaling pathways stimulated by the offending drug that produce corporal smooth muscle relaxation.
Clinical study
Besides observations of drug effectors of priapism, clinical assessments of the corrective effects of therapeutic prospects for the disorder have contributed to understanding its pathophysiology. Pharmaceutical approaches described to offer benefit include: intracorporal thrombolytic agents, which would support the pathogenic roles of blood stasis and thrombosis, 57, 58 oral diethylstilbestrol, which by exerting antiandrogenic effects would imply that androgens permit aberrant penile erection; 35 systemic injections of gonadotropin-releasing hormone analogues, which because they are also anti-androgenic would further hypotheses about the pathogenic role of androgens; 59, 60 lidocaine as a penile anesthetic block, which is considered to work by blunting sensory input conveyed in the dorsal nerve of the penis of reflexive erectile pathways; 61 oral and intracorporal alpha-adrenergic agonists, which exert contractile effects on erectile tissue, thus indicating the likely pathogenic role of uncontrolled non-adrenergic factors; 24, 60, 62, 63 intracorporal methylene blue, an antagonist of the nitric oxide/ cyclic guanosine monophosphate/protein kinase G effector mechanism of corporal smooth muscle relaxation, pointing to a possible pathogenic role of this biochemical pathway. 64, 65 Basic science investigation Basic research in the field has consisted mainly of identifying and evaluating animal models featuring priapic behavior and molecular studies that suggest possible mechanisms for the disorder. Transgenic mouse models of sickle cell disease display priapism supporting the idea that disturbed penile vascular homeostasis associated with the hematologic disease is pathophysiologic. 66 A mouse model of senility syndrome exhibits priapism, understood to occur on the basis of degeneration of medullary reticular formation neurons that normally inhibit male spinal sexual reflexes. 67 Mice lacking the genes for both neuronal and endothelial nitric oxide synthases display phasic erectile activity, indicating that the altered nitric oxide release affects the control mechanisms associated with penile erection. 68 After induction of prolonged erections or conditions of priapism in isolated cavernosal tissue experimentally in animals, the cavernosal tissue loses responsiveness to adrenergically stimulated tissue contraction, 69, 70 undergoes destructive metabolism via lipid peroxidation, 71 and increases expression of the tissue fibrosis marker transforming growth factor beta. 72 
Dysregulatory mechanisms
Since many regulatory factors are now known to influence the functional state of the cavernosal tissue, it is not surprising to consider that situations in which any of these factors go awry may lead to the development of priapism. This reference to erectile regulatory factors involved in priapism could apply to factors involved in corporal smooth muscle responses that operate somehow in a dysfunctional manner or to factors activated under the pathological conditions of priapism that adversely affect erectile tissue physiology. Dysregulatory mechanisms of erectile tissue function may be associated with idiopathic, stuttering, and other divergent presentations of priapism, conceivably distin-guished from the origins of classic hemodynamic types of priapism.
The current description of mediators and signal transduction pathways involved in penile erection suggests several scientifically plausible mechanisms that may contribute to the pathophysiology of priapism. Such mechanisms include: physiologic increases in oxygen tension within the cavernosal tissue, which stimulate corporal smooth muscle cell production and release of vasorelaxant substances while inhibiting the production and release of vasoconstrictive substances; 73, 74 heightened androgenic milieu, which promotes corporal neuromuscular transmission of penile erection; 75 altered composition of myosin isoforms and the extent of myosin phosphorylation in the corporal smooth musculature, which determines its level of basal tone; 76, 77 abnormal expression levels of ion channels and gap junctions in corporal smooth muscle cells, which could affect the tonicity and synchronicity of these cells; 78 aberrant nitric oxide regulation in the penis, which has been correlated with supraphysiologic erectile responses; 68, 79 intracorporal blood flow-related 'shear stress' forces that activate endothelial-based biochemical pathways sustaining penile erection. 80 
Prevention strategies
The development of prevention strategies for priapism expectedly will revolve around surveillance and early implementation of effective therapies. Individuals at risk for ischemic priapism, such as the hemodialysis patient or the patient with a hematologic dyscrasia, should be cautioned about the possible occurrence of the disorder under these circumstances while understandably basic attempts are undertaken to remedy the presumed causative etiology. Given the high level of alertness under these circumstances, standard therapies for management of the veno-occlusive pathology should be readily available. The risk of priapism with vasoactive pharmacotherapy for erectile dysfunction should be reduced with proper counseling regarding this risk and considerations for in-office test dosing, particularly for local or combined pharmacotherapies, to establish the best dose that would limit the risk subsequently.
Notwithstanding cases of unprecedented ischemic priapism, high-risk groups such as those with sickle cell disease manifesting 'stuttering' priapism and those exhibiting recurrent 'idiopathic' or neurologic priapism may be considered to have the greatest relevance for prevention efforts. These presentations arguably constitute the most clinically vexatious settings for priapism and would seem to benefit most from taking advance measures against the disorder. After all, these individuals fit a predictable pattern of progression to erectile tissue destruction in which, it would seem, clinical opportunities exist to gain disease control. Presently, current pharmacologic treatment successes support the roles of androgenic suppressive agents, 59 ,60 adrenergic agonist therapies, 24, 60, 62, 63 and effectors of the nitric oxide-dependent erection regulatory pathway in the penis such as methylene blue. 64, 65 As promising as these therapies have been, they still warrant certain considerations such as when they should be administered, whether they can be administered with minimal penile trauma and without causing adverse extra-penile effects, and whether they can be offered with a regimen that does not impair natural erections long term.
For the future, systematic development and application of therapies may result from improved understanding of the role of dysregulatory mechanisms of penile erection. This charge is consistent with current objectives to better understand the molecular mechanisms associated with the erectile tissue response. Therapies are anticipated that will target mechanisms involved in neurovascular transmission unique to the penis, corporal smooth muscle physiology, and biochemical regulation of erectile responses.
